Neurodegenerative disorders such as Alzheimer’s disease affect more than 270 million people worldwide. AD is the leading cause of dementia, resulting in memory loss due to atrophy of neurons in the hippocampus, which is the part of the brain that regulates learning and memory. Nanoparticles designed to carry drugs have emerged as a strategy for treating different diseases, but in the context of neurodegenerative disease, much of the research has focused on developing strategies for getting nanoparticles across the blood brain barrier and into targeted regions of the brain.